SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Reports that the U.S. would not strike Iran immediately sparked hopes for a relief bounce in SPY, but traders remain divided over whether tensions will ease or escalate, with oil and inflation risks in focus. The debate is unfolding ahead of a packed week of Fed, major technology earnings and inflation data that traders expect could add to volatility.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is drawing attention amid volatile natural-gas trading, with bearish traders pointing to mild-weather expectations, ample supply and storage builds, while bulls watch for colder forecasts, tighter inventories and supply disruptions to lift futures. Much of the debate also centers on BOILs daily leverage and futures-roll decay, which can magnify losses when natural gas does not rise quickly.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude rallies on fears of oil-supply disruptions tied to escalating Middle East tensions, including speculation about renewed strikes involving Iran and risks to shipping and regional energy infrastructure. Traders are divided between expecting further gains if supply risks persist and anticipating a sharp pullback if tensions ease or a deal emerges.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Attention is centered on Lillys upcoming quarterly report, with traders focused on Mounjaro and Zepbound demand and the possibility of stronger guidance. Bulls cite the companys growth and recent strength, while skeptics point to its high valuation and competition in oral GLP-1 drugs.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXTI is drawing attention for its sharp, volatile pullback after a major rally tied to AI data-center demand for indium-phosphide substrates and optical components. Bulls see the selloff as a buying opportunity based on the growth story, while bears point to the valuation, competition, and China-related supply risks.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

Brazils presidential runoff is driving EWZ attention, with traders positioning around the contest between Flvio Bolsonaro and Lula and the possibility of a market-moving result. The community notes a rally ahead of the vote but debates whether optimism is already priced in, while options activity reflects both upside bets and downside hedging.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios upcoming quarterly report is the main focus, with traders positioning around the stocks rebound into earnings. Discussion is split between optimism about AI-driven communications demand and concern that reported growth may overstate underlying organic growth because of carrier pass-through fees.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Positive prostate-cancer dataincluding results for ERLEADA and early activity from investigational JNJ-6143are driving discussion, with traders welcoming the pipeline potential. Some expect the news to support shares, while others question its near-term impact and whether the results are already priced in.

Valero Energy Corp. engages in the manufacture and marketing of transportation fuels and other petrochemical products. It operates through the following business segments: Refining, Ethanol and Renewable Diesel. The Refining segment consists of refining operations, associated marketing activities, and logistics assets that support its refining operations. The Ethanol segment includes its ethanol operations, associated marketing activities, and logistics assets that support its ethanol operations. The Renewable Diesel covers the operations of Diamond Green Diesel Holdings LLC. The company was founded in 1980 and is headquartered in San Antonio, TX.

Valero Energy Corp.

Valeros record quarterly results, driven by sharply stronger refining margins, are the main focus, but shares declined despite the earnings beat. Traders are debating a sell-the-news reaction, cautious guidance, and whether elevated fuel spreads can last.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

GDX is under pressure alongside golds pullback toward the psychologically important $4,000 level, with traders citing inflation concerns and expectations for higher interest rates as headwinds for precious metals. The community is split between bearish calls for more downside and dip-buyers watching support for a possible rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

Healthcare ETFs Are Looking Up: Here's Why 

Healthcare ETFs are hitting 52-week highs as earnings improve, dealmaking accelerates, FDA approvals stay strong and investors seek defensive growth.

Will Generic Drug Tariffs Impact Pharma ETFs?

New U.S. tariffs on generic drugs could pressure drugmakers and influence pharmaceutical ETFs. Here's what investors should watch.

Why Did CANF Stock Soar 25% Today?

Equity

The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

Invesco Exchange-Traded Fund Trust - Invesco Pharmaceuticals ETF

Neutral Sentiment

<ul class="summary-bullets"><li>The study enrolled 20 high-risk patients with advanced, metastatic disease who had received one or more prior therapies.</li><li>The company said that the secondary endpoints included overall and progression-free survival.</li><li>Can-Fite announced exercise of certain outstanding warrants to purchase up to 795,869 ADS at a reduced price of $5 per share.&nbsp;</li></ul>Shares of Can-Fite BioPharma (CANF) surged more than 40% in pre-market trading on Wednesday after the company reported positive results from its Phase 2A open-label study of namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had previously failed other treatments.The trial met its primary safety endpoint, showing that the drug was very well tolerated, with no new safety concerns observed. The study enrolled 20 high-risk patients with advanced, metastatic disease who had received one or more prior therapies.The company said that the secondary endpoints included overall and progression-free survival, with follow-up ongoing and one-third of patients still alive at data cut-off, as more mature results are expected to be presented at upcoming scientific meetings.Namodenoson is a selective A3 adenosine receptor agonist that has shown anti-tumor activity in preclinical models and is also being studied in advanced liver cancer. The drug has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.<h2 class="st-heading-2">Exercising of Warrants for $4.0 Million Proceeds</h2>Can-Fite BioPharma also announced a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to 795,869 American Depositary Shares at a reduced price of $5 per share, down from $9.34. The transaction is expected to close around March 5, 2026.&nbsp;In connection with the cash exercise, the company will issue new unregistered warrants to purchase up to 1,591,738 ADSs at $5 per share, exercisable for 24 months.&nbsp;Can-Fite expects gross proceeds of about $4.0 million to support research, clinical trials, and general corporate purposes.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CANF">CANF</a> on Stocktwits turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.<img src="https://news.stocktwits-cdn.com/CANF_jpg_27fa5e9013.webp" alt="CANF.jpg">One user said the company is a "great buyout candidate."<stembedurl>https://stocktwits.com/Pindis7/message/646561779</stembedurl>Year-to-date, the stock gained 63%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CANF company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

Can-Fite BioPharma Ltd.

Exchange Traded Concepts Trust - ETCT Loncar Cancer Immunotherapy ETF

Invesco Dynamic Pharmaceuticals ETF

SPDR Pharmaceuticals ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$125.03
Prev Close	$127.31
Open	$126.66
Dividend Yield	N/A
50-Day Moving Average	$125.83
Beta	N/A
Avg. Volume	41,790.70
PE Ratio	N/A

52-Week High	$131.68
52-Week Low	$94.89
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

PJP Fundamentals